Cigna's Evernorth to Offer Humira Biosimilar Without Out-of-Pocket Fee
By Ben Glickman
Cigna Group-owned Evernorth Health Services said Thursday it would provide a Humira biosimilar with no out-of-pocket fees starting in June.
The pharmacy and benefits provider said the biosimilar for Humira, used as a treatment for rheumatoid arthritis, Crohn's disease and other inflammatory conditions, would be available to eligible patients at its specialty pharmacy Accredo.
The company said the biosimilar price would be about 85% lower than the Humira list price. Evernorth said more than 100,000 Accredo patients currently use Humira or a biosimilar.
Plans for a $0 out-of-pocket Humira biosimilar offering was initially announced by Evernorth in March.
Write to Ben Glickman at ben.glickman@wsj.com
(END) Dow Jones Newswires
April 25, 2024 17:25 ET (21:25 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
These Stocks Are (Still) Powering the Bull Market
-
5 Undervalued Energy Stocks to Play the AI Data Center Demand Boom
-
After Earnings, Is Lowe’s Stock a Buy, Sell, or Fairly Valued?
-
5 Stocks With the Largest Fair Value Estimate Cuts After Q1 Earnings
-
10 Stocks With the Largest Fair Value Estimate Increases After Q1 Earnings
-
Markets Brief: Inflation Back in the Spotlight
-
AI Is Booming, but Consumer Spending Is Slowing. Which Will Prevail in the Stock Market?
-
What’s Happening In the Markets This Week
-
3 Dividend Stocks for June 2024
-
After Earnings, Is Alibaba Stock a Buy, Sell, or Fairly Valued?
-
MongoDB Earnings: Slashing Valuation as Execution and Macro to Blame for Lower Guidance
-
Marvell Earnings: We Raise Our Medium-Term AI Forecast and Bring Our Valuation Up to $75
-
Zscaler Earnings: Impressive Traction in Emerging Products Drives Sales Growth for the Quarter
-
Dell Earnings: Raising Valuation on Strong AI, but the Stock Remains Severely Overvalued
-
After Earnings, Is Nvidia Stock a Buy, Sell, or Fairly Valued?
-
The 10 Best Companies to Invest in Now